Please login to the form below

Not currently logged in
Email:
Password:

olesoxime

This page shows the latest olesoxime news and features for those working in and with pharma, biotech and healthcare.

Roche gains EU PRIME status for Spinraza rival

Roche gains EU PRIME status for Spinraza rival

Prior treatment could include olesoxime, an experimental drug Roche acquired as part of its takeover of Trophos three years ago that was abandoned earlier this year after a failed phase 2

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 675. Trophos/Roche. Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury.

  • Pharma deals during January 2015 Pharma deals during January 2015

    A few days later, the acquisition of the French company, Trophos was announced which brings Olesoxime an orphan drug in phase II clinical development for spinal muscular atrophy; plus TRO 40303

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...